Genor Biopharma Executive and Leadership Team

Feng Guo, the Chief Executive Officer at Genor Biopharma, directs the overarching corporate strategy and long-term vision for the organization. By overseeing the development of 15 targeted drug candidates, the Chief Executive Officer ensures alignment between research initiatives and commercialization goals. Feng Guo maintains rigorous oversight of the company's expansion within the competitive biopharmaceutical sector, specifically focusing on the Chinese market. This leadership role involves constant collaboration with the Board to secure resources for novel biological pathway research. Through the optimization of internal processes, the Chief Executive Officer drives sustainable growth and maintains the company's reputation for scientific excellence. By prioritizing patient-centric innovation, the Chief Executive Officer fosters a culture of high-performance research. Ultimately, the Chief Executive Officer secures the financial and operational health of the enterprise while navigating complex regulatory environments to bring life-saving oncology and autoimmune therapies to market.

Weng Chengyi, the Executive Director & Chief Financial Officer at Genor Biopharma, manages the fiscal health and capital allocation strategies for the entire organization. Overseeing the financial planning and analysis departments, the Executive Director & Chief Financial Officer ensures that the company maintains sufficient liquidity to support the development of 15 targeted drug candidates. Weng Chengyi directs the budgeting process, aligning financial resources with the strategic goals of the oncology and autoimmune research programs. This leadership role involves frequent reporting to investors and stakeholders regarding the company's market position and commercialization potential. By optimizing the capital structure, the Executive Director & Chief Financial Officer supports the long-term sustainability of the business model. The Executive Director & Chief Financial Officer also evaluates potential investment opportunities to expand the company's footprint in the global biopharmaceutical market. Through disciplined financial management, the Executive Director & Chief Financial Officer provides the stability necessary for continuous scientific advancement.

Paul Ni, the Chief Operating Officer (Genor Biopharma) at Genor Biopharma, executes the daily operational strategies that drive the company's manufacturing and supply chain efficiency. Overseeing the internal logistics and cross-departmental workflows, the Chief Operating Officer (Genor Biopharma) ensures that the organization meets its production targets for oncology and autoimmune drug candidates. Paul Ni manages the operational scale required to support clinical trials and eventual commercialization across the Chinese market. This role involves coordinating with the research and medical teams to ensure that operational capacity matches the pace of scientific discovery. By streamlining manufacturing processes, the Chief Operating Officer (Genor Biopharma) reduces time-to-market for critical therapies. The Chief Operating Officer (Genor Biopharma) also implements quality control measures to maintain compliance with international pharmaceutical standards. Through rigorous operational oversight, the Chief Operating Officer (Genor Biopharma) guarantees that the company's infrastructure supports the successful delivery of innovative treatments to patients.

Qibin Liang, the Chief Technology Officer at Genor Biopharma, architects the technical infrastructure required for advanced drug discovery and development. Overseeing the integration of cutting-edge laboratory technologies, the Chief Technology Officer ensures that the research pipeline remains at the forefront of the biopharmaceutical industry. Qibin Liang manages the technical teams responsible for validating novel biological pathways, which directly supports the company's mission to deliver effective oncology and autoimmune treatments. This role involves close coordination with the research department to streamline the transition from experimental data to clinical application. By implementing scalable technological solutions, the Chief Technology Officer enhances the efficiency of the drug development lifecycle. The Chief Technology Officer also monitors global technological trends to maintain a competitive edge in the pharmaceutical manufacturing space. Through precise technical oversight, the Chief Technology Officer guarantees that all research outputs meet the highest standards of scientific integrity and innovation.

Li Tong, the Chief Medical Officer at Genor Biopharma, directs the clinical development and medical strategy for the company's entire drug pipeline. Overseeing the design and execution of clinical trials, the Chief Medical Officer ensures that all research adheres to the highest safety and efficacy standards for oncology and autoimmune patients. Li Tong manages the medical affairs team, providing the scientific expertise necessary to validate novel biological pathways. This leadership role involves close collaboration with regulatory bodies to facilitate the approval of new therapies. By analyzing clinical data, the Chief Medical Officer informs the strategic direction of the research department, ensuring that the company focuses on high-potential drug candidates. The Chief Medical Officer also represents the company in medical forums, highlighting the clinical impact of the current pipeline. Through expert medical guidance, the Chief Medical Officer ensures that every therapeutic solution developed by the company addresses critical unmet needs in the global healthcare market.